Skip to main content

CORRECTION article

Front. Oncol., 25 September 2019
Sec. Women's Cancer
Volume 9 - 2019 | https://doi.org/10.3389/fonc.2019.00967
This article is part of the Research Topic New Approaches to Classification and Diagnostic Prediction of Breast Cancers View all 18 articles

Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution

This article is a correction to:

  1. PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution

    1. Read original article
\nSonia Pernas Sonia Pernas1*Anna PetitAnna Petit2Fina ClimentFina Climent2Laia ParLaia Paré3J. Perez-MartinJ. Perez-Martin4Luz VenturaLuz Ventura1Milana BergaminoMilana Bergamino1Patricia GalvnPatricia Galván3Catalina FaloCatalina Falo1Idoia MorillaIdoia Morilla1Adela Fernandez-OrtegaAdela Fernandez-Ortega1Agostina StradellaAgostina Stradella1Montse ReyMontse Rey5Amparo Garcia-TejedorAmparo Garcia-Tejedor6Miguel Gil-GilMiguel Gil-Gil1Aleix Prat Aleix Prat3*
  • 1Department of Medical Oncology-Breast Cancer Unit, Institut Català d'Oncologia (ICO)-H.U.Bellvitge-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain
  • 2Department of Pathology-Breast Cancer Unit, Institut Català d'Oncologia (ICO)-H.U.Bellvitge-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain
  • 3Department of Medical Oncology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain
  • 4Clinical Research Unit, Institut Català d'Oncologia (ICO)-L'Hospitalet, Barcelona, Spain
  • 5Department of Pharmacy, Institut Català d'Oncologia (ICO)-L'Hospitalet, Barcelona, Spain
  • 6Department of Gynecology-Breast Cancer Unit, Institut Català d'Oncologia (ICO)-H.U.Bellvitge-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain

A Corrigendum on
PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution

by Pernas, S., Petit, A., Climent, F., Paré, L., Perez-Martin, J., Ventura, L., et al. (2019). Front. Oncol. 9:707. doi: 10.3389/fonc.2019.00707

In the original article, there was a mistake in Figure 1 as published. The colors of the labels used for Figures 1B,D were incorrect. pCR should be in red and non-pCR should be in blue. The corrected Figure 1 appears below.

FIGURE 1
www.frontiersin.org

Figure 1. Disease Free Survival of the entire cohort (A) and based on pathological complete response (pCR) (B). Overall Survival (OS) of the entire cohort (C) and based on pCR (D).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: breast cancer, HER2, pathological complete response, gene expression, molecular intrinsic subtype, residual disease, paired samples

Citation: Pernas S, Petit A, Climent F, Paré L, Perez-Martin J, Ventura L, Bergamino M, Galván P, Falo C, Morilla I, Fernandez-Ortega A, Stradella A, Rey M, Garcia-Tejedor A, Gil-Gil M and Prat A (2019) Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution. Front. Oncol. 9:967. doi: 10.3389/fonc.2019.00967

Received: 21 August 2019; Accepted: 11 September 2019;
Published: 25 September 2019.

Edited and reviewed by: Michael Gnant, Medical University of Vienna, Austria

Copyright © 2019 Pernas, Petit, Climent, Paré, Perez-Martin, Ventura, Bergamino, Galván, Falo, Morilla, Fernandez-Ortega, Stradella, Rey, Garcia-Tejedor, Gil-Gil and Prat. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Sonia Pernas, spernas@iconcologia.net; Aleix Prat, alprat@clinic.cat

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.